Tobira Therapeutics
Sep 1, 2016

Tobira Therapeutics to Participate in Two Conferences in September

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the following conferences in September.

A live webcast and 30-day archive of these presentations will be available at

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

Tobira Investor & Media Contact:
Ian Clements, Ph.D., +1 650-351-5013
BrewLife Media Contact:
Kelly Boothe, Ph.D., +1 425-946-1076

Source: Tobira Therapeutics, Inc.

News Provided by Acquire Media